Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study.

被引：16
|
作者：
Chau, Ian
Bendell, Johanna C.
Calvo, Emiliano
-Davila, Rafael Santana
Arkenau, Hendrik-Tobias
Mi, Gu
Jin, Jin
Rege, Jessicca
Ferry, David
Herbst, Roy S.
Fuchs, Charles S.
机构：
[1] Royal Marsden Hosp, Sutton, Surrey, England
[2] PLLC, Sarah Cannon Res Inst & Tennessee Oncol, Nashville, TN USA
[3] Ctr Integral Oncol Clara Campal, START Madrid HM CIOCC, Early Clin Drug Dev Program, Madrid, Spain
[4] Univ Washington, Div Med Oncol, Seattle, WA 98195 USA
[5] Sarah Cannon Res Inst UK, London, England
[6] Eli Lilly & Co, Indianapolis, IN 46285 USA
[7] Eli Lilly & Co, Bridgewater, NJ USA
[8] Yale Sch Med, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.4046
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4046
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Safety and efficacy of ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: a multi-disease phase 1 study
    Thuss-Patience, P.
    Vasile, E.
    Chau, I
    Penel, N.
    Mi, G.
    Emig, M.
    Fuchs, C. S.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 254 - 255
  • [2] Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Preliminary results from a multi-disease phase I study (JVDF)
    Chau, Ian
    Penel, Nicolas
    Arkenau, Hendrik-Tobias
    Santana-Davila, Rafael
    Calvo, Emiliano
    Soriano, Andres O.
    Mi, Gu
    Jin, Jin
    Ferry, David
    Herbst, Roy S.
    Fuchs, Charles S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [3] Safety and antitumor activity from the phase lb study of ramucirumab plus pembrolizumab in treatment-naive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF)
    Chau, I.
    Bendell, J.
    Soriano, A.
    Arkenau, H.
    Cultreras, J.
    Santana-Davila, R.
    Calvo, E.
    Le Toumeau, C.
    Zender, L.
    Mi, G.
    Schelman, W.
    Ferry, D.
    Herbst, R.
    Fuchs, C.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 122 - 122
  • [4] Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P).
    Chau, Ian
    Bendell, Johanna C.
    Calvo, Emiliano
    Santana-Davila, Rafael
    Ahnert, Jordi Rodon
    Penel, Nicolas
    Arkenau, Hendrik-Tobias
    Yang, Jing
    Rege, Jessicca
    Mi, Gu
    Ferry, David
    Herbst, Roy S.
    Fuchs, Charles S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [5] Previously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): Efficacy and safety data
    Herbst, R. S.
    Martin-Liberal, J.
    Calvo, E.
    Isambert, N.
    Bendell, J.
    Cassier, P.
    Jin, J.
    Mi, G.
    Rege, J.
    Paz-Ares, L.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [6] Ramucirumab plus pembrolizumab in previously treated advanced or metastatic biliary tract cancer: A multi-disease phase 1 study
    Hendrik-Tobias, Arkenau
    Johanna, Bendell
    Roy, Herbst
    Gu, Mi
    Jin, Jin
    Jessicca, Rege
    David, Ferry
    Ian, Chau
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [7] KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer
    Shitara, K.
    Ozguroglu, M.
    Bang, Y. J.
    Di Bartolomeo, M.
    Mandala, M.
    Ryu, M. H.
    Fornaro, L.
    Olesinski, T.
    Caglevic, C.
    Chung, H.
    Muro, K.
    Gokkurt, E.
    Mansoor, W.
    McDermott, R.
    Schacham-Shmueli, E.
    Chen, X.
    Kang, S. P.
    Mayo, C.
    Ohtsu, A.
    Fuchs, C.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [8] Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
    Tabernero, Josep
    Van Cutsem, Eric
    Bang, Yung-Jue
    Fuchs, Charles S.
    Wyrwicz, Lucjan
    Lee, Keun Wook
    Kudaba, Iveta
    Garrido, Marcelo
    Chung, Hyun Cheol
    Salguero, Hugo Raul Castro
    Mansoor, Wasat
    Braghiroli, Maria Ignez Freitas Melro
    Goekkurt, Eray
    Chao, Joseph
    Wainberg, Zev A.
    Kher, Uma
    Shah, Sukrut
    Kang, SoonMo Peter
    Shitara, Kohei
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (18)
  • [9] A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results
    Herbst, Roy S.
    Bendell, Johanna C.
    Isambert, Nicolas
    Calvo, Emiliano
    Santana-Davila, Rafael
    Cassier, Philippe
    Perez-Gracia, Jose Luis
    Yang, Jing
    Rege, Jessicca
    Ferry, David
    Mi, Gu
    Chau, Ian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA).
    Catenacci, Daniel V. T.
    Park, Haeseong
    Lockhart, A. Craig
    Gold, Philip Jordan
    Enzinger, Peter C.
    Nordstrom, Jeffrey L.
    Hong, Sam
    Hochster, Howard S.
    Kelly, Ronan Joseph
    Uronis, Hope Elizabeth
    Bendell, Johanna C.
    Oh, Sang Cheul
    Park, Se Hoon
    Kim, Yeul Hong
    Kang, Yoon-Koo
    Lee, Keun-Wook
    Ng, Matthew C. H.
    Wigginton, Jon M.
    Davidson-Moncada, Jan Kenneth
    Bang, Yung-Jue
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345